Proposal in Congress

Combating Illicit Xylazine Act

Record date · Apr 15, 2026

What this means

Status
Proposal in Congress
What happened
Combating Illicit Xylazine Act This bill regulates xylazine under the Controlled Substances Act (CSA). Xylazine, also known as tranq , is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine. This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III con…
What to check next
See the latest action below for the next step in Congress.
Check the original record

About this record

Combating Illicit Xylazine Act This bill regulates xylazine under the Controlled Substances Act (CSA). Xylazine, also known as tranq , is a nonopioid sedative and pain reliever that is approved for use in animals. Recently, the Drug Enforcement Administration (DEA) has reported an increase in trafficking of fentanyl mixed with xylazine. This bill adds xylazine, including its salts, isomers, and salts of isomers, to schedule III of the CSA. Schedule III controlled substances, including anabolic steroids, buprenorphine, and ketamine, have less potential for abuse than a schedule I or II substance, have a currently accepted medical use, and have low or moderate risk of dependence if abused. Under the bill, manufacturing, distributing, or dispensing xylazine, or possessing with intent to manufacture, distribute, or dispense xylazine for illicit use is subject to criminal penalties under the CSA. The bill also requires xylazine transactions to be tracked in the drug reporting system maintained by the DEA. The bill exempts from registration under the CSA persons and entities that possess xylazine (1) lawfully dispensed by a veterinarian or pharmacy and (2) for an animal or for use in certain animal-control or wildlife programs. The bill also exempts xylazine manufacturers from the CSA's physical security requirements. Finally, the bill requires the DEA, in coordination with the Department of Health and Human Services (HHS), to provide Congress with a report on how the agencies previously determined whether xylazine should be a controlled substance, including the full text of HHS's recommendations to the DEA for scheduling xylazine.

Record details

Bill number
S. 545
Congress
119
Introduced
2025-02-12
Sponsor
Sen. Cortez Masto, Catherine [D-NV]
Committees
Judiciary Committee
Latest documented action
Placed on Senate Legislative Calendar under General Orders. Calendar No. 372.

Documented actions

  1. Placed on Senate Legislative Calendar under General Orders. Calendar No. 372.

  2. Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.

  3. Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.

  4. Read twice and referred to the Committee on the Judiciary.

  5. Introduced in Senate

Sources and related records

Source checked .